BAGNASCO, DIEGO
 Distribuzione geografica
Continente #
EU - Europa 4.508
Totale 4.508
Nazione #
IT - Italia 4.508
Totale 4.508
Città #
Genova 2.934
Genoa 817
Rapallo 724
Bordighera 33
Totale 4.508
Nome #
Clinical characteristics, management and in-hospital mortality of patients with COVID-19 In Genoa, Italy 142
Mepolizumab in the management of severe eosinophilic asthma in adults: Current evidence and practical experience 133
A critical evaluation of Anti-IL-13 and Anti-IL-4 strategies in severe asthma 132
Molecular phenotyping and biomarker development: Are we on our way towards targeted therapy for severe asthma? 131
Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma 131
Personalized medicine in allergy 123
Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life 119
Anti-IL-5 and IL-5Ra: Efficacy and safety of new therapeutic strategies in severe uncontrolled asthma 118
The safety of monoclonal antibodies in asthma 116
Efficacy of mepolizumab in patients with previous omalizumab treatment failure: Real-life observation 116
Current insights in allergen immunotherapy 115
When to stop biologicals. Severe asthma exacerbation after mepolizumab discontinuation 115
Biosimilars in allergic diseases 112
Sleep complaints and sleep breathing disorders in upper and lower obstructive lung diseases 109
Targeting Interleukin-5 or Interleukin-5Rα: Safety Considerations 107
MK-8237: a house dust mite vaccine for treating allergic rhinitis, asthma and atopic dermatitis 107
Benefit of SLIT and SCIT for Allergic Rhinitis and Asthma 106
Umeclidinium for the treatment of uncontrolled asthma 104
Reslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine? 103
The path to personalized medicine in asthma 102
Multiple pulmonary nodules and unexplained fever: when the pulmonologist fails. 101
Update on immunotherapy for the treatment of asthma 94
Pharmacokinetics and pharmacodynamics of monoclonal antibodies for asthma treatment 87
The North-Western Italian experience with anti IL-5 therapy amd comparison with regulatory trials 85
Severe asthma, biologicals, and auto-injection: Yes, no, may be! 84
30 Years Of Sublingual Immunotherapy 83
Prevalence and prognostic value of cardiac troponin in elderly patients hospitalized for COVID-19 81
Cabbage and fermented vegetables: From death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID-19 80
One year of mepolizumab. Efficacy and safety in real-life in Italy 79
IL-13 and idiopathic pulmonary fibrosis: Possible links and new therapeutic strategies 75
Mepolizumab in severe asthma: evidence in real-life 75
Biologicals for severe asthma: what we can learn from real-life experiences? 74
The importance of being not significant: blood eosinophils and clinical responses do not correlate in severe asthma patients treated with Mepolizumab in real life 74
Clinical characteristics, management and in-hospital mortality of patients with coronavirus disease 2019 in Genoa, Italy 70
Efficacy and safety of honeybee and wasp tyrosine-adsorbed venom immunotherapy 69
Impact of tDCS on persistent COVID-19 olfactory dysfunction: a double-blind sham-controlled study 67
Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs 63
Adherence to Allergen Subcutaneous Immunotherapy is Increased by a Shortened Build-Up Phase: A Retrospective Study 60
Evolving phenotypes to endotypes: is precision medicine achievable in asthma? 59
Biological agents for severe asthma: the evolution of the at-home self-injection approach. 51
ARIA-ITALY multidisciplinary consensus on nasal polyposis and biological treatments 51
null 49
Minimal clinically important difference for asthma endpoints: An expert consensus report 47
Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life 47
Application of bioendoscopy filters in endoscopic assessment of sinonasal Schneiderian papillomas 47
Extensive activation, tissue trafficking, turnover and functional impairment of NK cells in COVID-19 patients at disease onset associates with subsequent disease severity 47
FEV6 assessment in spirometric abnormalities screening: the first population-based study in Italian pharmacies 41
Anti-il5 therapies for severe eosinophilic asthma: Literature review and practical insights 39
Asthma in a large COVID-19 cohort: Prevalence, features, and determinants of COVID-19 disease severity 38
Severe asthma: One disease and multiple definitions 26
Nrf2-interacting nutrients and COVID-19: time for research to develop adaptation strategies 25
Biologics in Severe Eosinophilic Asthma: Three-Year Follow-Up in a SANI Single Center 24
Cerebrospinal Fluid Leak Repair: Usefulness of Intrathecal Fluorescein for Correct Topographic Identification of the Skull Base Defects 23
Significant improvement in lung function and asthma control after benralizumab treatment for severe refractory eosinophilic asthma 21
A case of chronic eosinophilic pneumonia in a patient treated with dupilumab 20
Kidney disease and all-cause mortality in patients with COVID-19 hospitalized in Genoa, Northern Italy 18
Personalized and Precision Medicine in Asthma and Eosinophilic Esophagitis: The Role of T2 Target Therapy 18
Aspergillus-related diseases in a cohort of patients with severe asthma: A SANI single-center report 18
Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI) 17
Biologics and Bronchial Thermoplasty for severe refractory asthma treatment: From eligibility criteria to real practice. A cross-sectional study 17
Do the current guidelines for asthma pharmacotherapy encourage over-treatment? 15
Biologics for the Treatments of Allergic Conditions: Severe Asthma 15
Epithelial dysfunction, respiratory infections and asthma: the importance of immunomodulation. A focus on OM-85 14
Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders 13
Personalizing the approach to asthma treatment 13
Real-life studies in allergen immunotherapy 13
Prospective Italian real-world study of mepolizumab in severe eosinophilic asthma validates retrospective outcome reports 12
COVID-19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: Results from a multicenter Italian survey 12
Quick Olfactory Sniffin’ Sticks Test (Q-Sticks) for the detection of smell disorders in COVID-19 patients 11
Real-life studies of biologics used in asthma patients: key differences and similarities to trials 10
Effectiveness and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps and associated comorbidities: a multicentric prospective study in real life 9
Impulse oscillometry defined small airway dysfunction in asthmatic patients with normal spirometry: Prevalence, clinical associations, and impact on asthma control 9
Severe chronic rhinosinusitis treated with dupilumab, a real-life analysis of early effectiveness 8
COPD, but Not Asthma, Is Associated with Worse Outcomes in COVID-19: Real-Life Data from Four Main Centers in Northwest Italy 8
Diagnostic therapeutic assistance pathway (PDTA) of type 2 chronic rhinosinusitis 7
Severe Asthma Network Italy Definition of Clinical Remission in Severe Asthma: A Delphi Consensus 6
Nasal cytology as a reliable non-invasive procedure to phenotype patients with type 2 chronic rhinosinusitis with nasal polyps 5
Benralizumab Efficacy in Late Non-Responders to Mepolizumab and Variables Associated with Occurrence of Switching: A Real-Word Perspective 4
Comparing a fixed combination of budesonide/formoterol with other inhaled corticosteroid plus long-acting beta-agonist combinations in patients with chronic obstructive pulmonary disease: a review 4
Different aspects of severe asthma in real life: Role of Staphylococcus aureus enterotoxins and correlation to comorbidities and disease severity 4
Management of Patients with Severe Asthma and Chronic Rhinosinusitis with Nasal Polyps: A Multidisciplinary Shared Approach 4
Specific Therapy for T2 Asthma 3
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Focus on the Pathophysiological and Diagnostic Role of Viruses 3
COVID-19, Eosinophils, and Biologicals for Severe Asthma 2
null 2
Efficacy and steroid-sparing effect of benralizumab: Has it an advantage over its competitors? 2
Mepolizumab in Patients With Severe Asthma and Comorbidities: 1-Year REALITI-A Analysis 1
Omalizumab and cancer risk: Current evidence in allergic asthma, chronic urticaria, and chronic rhinosinusitis with nasal polyps 1
Personalized medicine and allergen immunotherapy: the beginning of a new era? 1
The new indications for biologicals in type 2 diseases: perspectives 1
Epithelial dysfunction, respiratory infections and asthma: the importance of immunomodulation. A focus on OM-85 1
Type 2 immunity in asthma 1
Strategies to reduce corticosteroid-related adverse events in asthma 1
New suggestions in sublingual immunotherapy for house dust mite-related allergic diseases 1
Severe asthma, biologicals, and auto-injection: Yes, no, may be! 1
New suggestions in sublingual immunotherapy for house dust mite-related allergic diseases 1
Strategies to reduce corticosteroid-related adverse events in asthma 1
Reduction of oral corticosteroids in patients with severe eosinophilic asthma treated with Benralizumab: could it represent a marker of treatment efficacy? 1
Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis 1
Small airway dysfunction and poor asthma control: a dangerous liaison 1
Totale 4.707
Categoria #
all - tutte 18.782
article - articoli 18.599
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 37.381


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.304 39 19 45 124 126 160 204 127 142 161 122 35
2020/2021716 31 45 51 58 65 39 38 61 42 91 46 149
2021/2022595 21 11 17 63 15 72 23 130 53 76 14 100
2022/2023874 67 77 8 72 89 127 73 42 153 54 96 16
2023/2024724 42 82 9 82 49 183 43 44 37 14 49 90
2024/202518 18 0 0 0 0 0 0 0 0 0 0 0
Totale 4.707